XencorXNCR +3.93%52 FCF Margin % is -1,511.03% as of Mar. 2026. GuruFocus rates XNCR with a GF Score™ of 52/100 and a GF Value™ of $9.60 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 959 Biotechnology companies, Xencor ranks worse than 60.48% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Xencor's Free Cash Flow for the
three
months ended in Mar. 2026 was $-68.24 Mil. Xencor's Revenue for the
three
months ended in Mar. 2026 was $4.52 Mil. Therefore, Xencor's FCF Margin % for the quarter that ended in Mar. 2026 was -1,511.03%.
The historical rank and industry rank for Xencor's FCF Margin % or its related term are showing as below:
XNCR'
s FCF Margin % Range Over the Past 10 Years
Min: -218.96 Med: -36.05 Max: 84.6
Current: -193.96
During the past 13 years, the highest FCF Margin % of Xencor was 84.60%. The lowest was -218.96%. And the median was -36.05%.
XNCR's FCF Margin % is ranked worse than 60.48% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs XNCR: -193.96
Xencor FCF Margin % Related Terms
Xencor FCF Margin % Historical Data
* Premium members only.
The historical data trend for Xencor's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Xencor's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xencor FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xencor's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Xencor's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xencor (XNCR) has a FCF Margin % of -1,511.03% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Xencor and its competitors. According to the industry distribution chart, Xencor ranks #580 out of 959 companies in the Biotechnology industry, placing it in the top 60.5%.
Is Xencor's FCF Margin % too high?
Xencor's current FCF Margin % is -1,511.03%. Based on the distribution chart, Xencor ranks #580 out of 959 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Xencor has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xencor's FCF Margin % compare to ORIC and ANNX?
According to the Biotechnology industry distribution chart, Xencor ranks #580 out of 959 companies for FCF Margin %. This places Xencor in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Xencor and its competitors. Xencor's current FCF Margin % is -1,511.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xencor stock overvalued right now?
Based on GuruFocus' analysis, Xencor (XNCR) is currently considered Significantly Overvalued. The stock's GF Value™ is $9.60, compared to a current price of $15.33 — trading 59.7% above its estimated fair value. The current FCF Margin % is -1,511.03%. Xencor's overall GF Score™ is 52/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Xencor (XNCR), the current FCF Margin % is -1,511.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xencor (XNCR) Overvalued in 2026?
Based on GuruFocus' analysis, Xencor stock appears to be overvalued.
The current stock price of $15.33 is trading 59.7% above its estimated GF Value™ of $9.60.
GuruFocus considers Xencor to be Significantly Overvalued.
Key valuation signals for XNCR:
FCF Margin %: -1,511.03%
GF Value™: $9.60 vs. price of $15.33 (59.7% above fair value)
No single metric tells the full story. See the XNCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
52GF Score
Get the complete analysis for XNCR
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XNCR has been successfully added to your 
